Clinical Research Directory
Browse clinical research sites, groups, and studies.
Personalization of Long-Term Antiplatelet Therapy - RAPID EXTEND
Sponsor: Ottawa Heart Institute Research Corporation
Summary
In patients after myocardial infarction (MI) (heart attacks) and treated with percutaneous coronary intervention (PCI), the current standard is dual antiplatelet therapy (DAPT), with aspirin and a P2Y12 receptor inhibitor, for 1 year of treatment. At 1 year, there are several options including: i) Ongoing DAPT (with aspirin and ticagrelor), ii) Selective treatment use of a P2Y12 inhibitor based on risk profiles. This study is a pilot vanguard study to evaluate several strategies for choosing anti-platelet regimen among patients post MI and PCI at 1 year.
Official title: Personalization of Long-Term Antiplatelet Therapy Using a Novel Combined Demographic/Pharmacogenomic Strategy - The RAPID EXTEND Randomized Study
Key Details
Gender
All
Age Range
50 Years - Any
Study Type
INTERVENTIONAL
Enrollment
39
Start Date
2019-08-22
Completion Date
2026-02-26
Last Updated
2026-05-06
Healthy Volunteers
No
Interventions
Active Comparator: Dual Antiplatelet Therapy (DAPT) - Aspirin 81 mg + Ticagrelor 60mg twice daily
DAPT with aspirin and ticagrelor
Ticagrelor Monotherapy: Ticagrelor 60 mg twice daily
Ticagrelor monotherapy
Personalized Therapy Arm: Aspirin 81 mg or Ticagrelor 60mg twice daily or Clopidogrel 75 mg once daily
Personalized therapy based on risk score and genotyping
Locations (1)
University of Ottawa Heart Institute
Ottawa, Ontario, Canada